Member Login
Press
PULMONARY DEVICE MARKET TO DOUBLE TO MORE THAN $3 BILLION IN 2011 AS NEW TECHNOLOGIES
DRIVE IMPROVED DIAGNOSIS AND TREATMENT OF LARGE PATIENT POPULATIONS
CLEVELAND-July 2007--(BUSINESS WIRE)--Pulmonary disease remains one of the major untapped medical device opportunities in the U.S. Not only are most of the diagnostic technologies employed underutilized, but treatment options have been limited. Sleep apnea was the first pulmonary disease to demonstrate the market potential of pulmonary devices, and its potential is far from peaking. Emerging minimally invasive and interventional therapies for asthma and COPD are preparing to drive similar, significant growth as they improve outcomes for drug-refractory patients and stimulate diagnostic testing. Finally, new technologies are expected to enable screening and, hence, earlier diagnosis and characterization of a full range of pulmonary diseases, further expanding caseloads. The result of these synergistic trends will be a two-fold increase in sales of pulmonary devices to more than $3 billion in 2011, which will represent only partial realization of the potential of this important market.
These are among the findings of a new report from Health Research International entitled "Opportunities in U.S. Pulmonary Device Markets," which is being distributed exclusively by Life Science Intelligence. This 400 page report contains more than 115 exhibits, including market models and supplier share data for: diagnostic spirometry products, pulmonary function testing systems, lung CAD systems, flexible bronchoscopes, peak flow meters, stationary and portable oxygen concentrators, chest compression systems, bronchial thermotherapy, interventional bronchoscopy devices, diaphragm pacing technologies, other emerging COPD therapies, polysomnographs (PSGs) and non-PSG sleep apnea diagnostics, traditional sleep apnea products (CPAP, Bilevel and autoPAP systems) and adaptive servo-ventilation products. A detailed epidemiological analysis explains the drivers of asthma, COPD, lung cancer and sleep apnea caseloads, and detailed profiles are presented for 14 key suppliers. Among the approximately 100 companies whose technologies and strategies are covered in this report are: Advanced Brain Monitoring, Aeris Therapeutics, AirSep, ALung Technologies, Asthmatx, Broncus Technologies, Covidien, Deep Breeze Medical, DeVilbiss Healthcare, EDDA Technology, Emphasys Medical, Fisher & Paykel Healthcare, Flaga Group, Haemair, Hill-Rom, Hologic/R2 Technology, Invacare, Jones Medical Instrument, Medical Graphics/Angeion, Novalung, nSpire Health, Olympus America, PneumRx, Pulmonx, ResMed, Respironics, Riverain Medical, Rox Medical, Spiration, superDimension, Synapse Biomedical, Uptake Medical, Viasys Healthcare and Xillix Technologies, among others.
Additional details on Opportunities in U.S. Pulmonary Device Markets can be found at http://www.lifescienceintelligence.com/pulmonary
About Health Research International
Founded in 1978, Health Research International ( www.healthri.com ) provides the pharmaceutical and medical device industries with reliable, comprehensive and meticulously researched market analysis that incorporates strategic vision and a thorough understanding of competing medical technologies. Quality, experience and follow through have been the cornerstones of their custom consulting, online surveys, pricing sensitivity studies, FDA work and market reports.
About Life Science Intelligence
Life Science Intelligence ( www.lifescienceintelligence.com ) delivers high quality market data and information to medical technology executives, entrepreneurs and investors. LSI produces its own information products and partners with select top tier information companies to distribute their high end information.